Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.
Start 7-day free trial → Log in

Nenocorilant · CORT125236, HY-147293

Small molecule · developed by Corcept Therapeutics

Phase 1/2 Most advanced trial
CORT Developer
1 Registered trials

What is Nenocorilant?

Nenocorilant is an investigational small-molecule drug studied in Neoplasms.

At a glance

Also known as
CORT125236, HY-147293
Drug type
Small molecule
Therapy area
Oncology
Developer
Corcept Therapeutics (CORT)
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 1/2
UNII
MV83V7AT2Z

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT07276373 Phase 1/2 Neoplasms Recruiting CORT

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Neoplasms

More from Corcept Therapeutics

Relacorilant FDA approved CORT125236 Phase 1 CORT125329 Phase 1 Dazucorilant Phase 2 Exicorilant Phase 1/2 Miricorilant Phase 2

Sources

Updated Oct 3, 2026. Something wrong or missing? Report it on the CORT page.

Follow CORT, the company behind Nenocorilant

See CORT's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

CORT catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.